{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:50:55Z","timestamp":1791305455823,"version":"4.3.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11095-026-04166-5","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:51:26Z","timestamp":1788213086000},"page":"3105-3123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual C20 Fatty Acid-Conjugated Insulin Analog LPJT-026: Enhanced HSA Binding, Prolonged PK\/PD Profiles, and Reduced Hypoglycemia Risk for Biweekly Diabetes Therapy"],"prefix":"10.1007","volume":"43","author":[{"given":"Yiwei","family":"Tou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuyi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qishen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"4166_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-022-01607-4","volume":"21","author":"MA Nauck","year":"2022","unstructured":"Nauck MA, D\u2019Alessio DA. Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21:169. https:\/\/doi.org\/10.1186\/s12933-022-01607-4.","journal-title":"Cardiovasc Diabetol"},{"key":"4166_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110718","volume":"201","author":"APS Kong","year":"2023","unstructured":"Kong APS, Lim S, Yoo SH, et al. Asia-Pacific consensus recommendations for application of continuous glucose monitoring in diabetes management. Diabetes Res Clin Pract. 2023;201: 110718. https:\/\/doi.org\/10.1016\/j.diabres.2023.110718.","journal-title":"Diabetes Res Clin Pract"},{"key":"4166_CR3","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327:534\u201345. https:\/\/doi.org\/10.1001\/jama.2022.0078.","journal-title":"JAMA"},{"key":"4166_CR4","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1001\/jama.2021.7444","volume":"325","author":"T Martens","year":"2021","unstructured":"Martens T, Beck RW, Bailey R, et al. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA. 2021;325:2262\u201372. https:\/\/doi.org\/10.1001\/jama.2021.7444.","journal-title":"JAMA"},{"key":"4166_CR5","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1111\/dom.15742","volume":"26","author":"SK Garg","year":"2024","unstructured":"Garg SK, Hirsch IB, Repetto E, et al. Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis. Diabetes Obes Metab. 2024;26:5202\u201310. https:\/\/doi.org\/10.1111\/dom.15742.","journal-title":"Diabetes Obes Metab"},{"key":"4166_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1210\/endrev\/bnae002","volume":"45","author":"J Rosenstock","year":"2024","unstructured":"Rosenstock J, Juneja R, Beals JM, et al. The basis for weekly insulin therapy: evolving evidence with insulin icodec and insulin efsitora alfa. Endocr Rev. 2024;45:379\u2013413. https:\/\/doi.org\/10.1210\/endrev\/bnae002.","journal-title":"Endocr Rev"},{"key":"4166_CR7","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s40259-024-00672-3","volume":"38","author":"HA Blair","year":"2024","unstructured":"Blair HA. Insulin icodec: first approval. BioDrugs. 2024;38:717\u201324. https:\/\/doi.org\/10.1007\/s40259-024-00672-3.","journal-title":"BioDrugs"},{"key":"4166_CR8","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1001\/jama.2023.19687","volume":"330","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Fr\u00edas JP, Rodbard HW, et al. Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial. JAMA. 2023;330:1631\u201340. https:\/\/doi.org\/10.1001\/jama.2023.19687.","journal-title":"JAMA"},{"key":"4166_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15414","volume":"41","author":"H Schaffner","year":"2024","unstructured":"Schaffner H, Wiener J, DeLuca A, et al. Insulin icodec: a novel once-weekly treatment for diabetes. Diabet Med. 2024;41: e15414. https:\/\/doi.org\/10.1111\/dme.15414.","journal-title":"Diabet Med"},{"key":"4166_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645617","volume":"12","author":"JJ Meier","year":"2021","unstructured":"Meier JJ. Efficacy of semaglutide in a subcutaneous and an oral formulation. Front Endocrinol (Lausanne). 2021;12: 645617. https:\/\/doi.org\/10.3389\/fendo.2021.645617.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4166_CR11","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.7326\/M23-0588","volume":"176","author":"HS Bajaj","year":"2023","unstructured":"Bajaj HS, Aberle J, Davies M, et al. Once-weekly insulin icodec with dosing guide app versus once-daily basal insulin analogues in insulin-naive type 2 diabetes (ONWARDS 5): a randomized trial. Ann Intern Med. 2023;176:1476\u201385. https:\/\/doi.org\/10.7326\/M23-0588.","journal-title":"Ann Intern Med"},{"key":"4166_CR12","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1111\/dom.15690","volume":"26","author":"RM Bergenstal","year":"2024","unstructured":"Bergenstal RM, Philis-Tsimikas A, Wysham C, et al. Once-weekly insulin efsitora alfa: design and rationale for the QWINT phase 3 clinical development programme. Diabetes Obes Metab. 2024;26:3020\u201330. https:\/\/doi.org\/10.1111\/dom.15690.","journal-title":"Diabetes Obes Metab"},{"key":"4166_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108145","volume":"164","author":"W Hanif","year":"2020","unstructured":"Hanif W, Patel V, Ali SN, et al. The South Asian Health Foundation (UK) guidelines for managing diabetes during Ramadan. Diabetes Res Clin Pract. 2020;164: 108145. https:\/\/doi.org\/10.1016\/j.diabres.2020.108145.","journal-title":"Diabetes Res Clin Pract"},{"key":"4166_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/dom.12042","volume":"15","author":"SC Gough","year":"2013","unstructured":"Gough SC, Harris S, Woo V, et al. Insulin degludec: overview of a novel ultra long-acting basal insulin. Diabetes Obes Metab. 2013;15:301\u20139. https:\/\/doi.org\/10.1111\/dom.12042.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"4166_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/dom.14593","volume":"24","author":"R Retnakaran","year":"2022","unstructured":"Retnakaran R, Zinman B. The ongoing evolution of basal insulin therapy over 100 years and its promise for the future. Diabetes Obes Metab. 2022;24(Suppl 1):17\u201326. https:\/\/doi.org\/10.1111\/dom.14593.","journal-title":"Diabetes Obes Metab"},{"key":"4166_CR16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10529-022-03248-7","volume":"44","author":"S Bhoria","year":"2022","unstructured":"Bhoria S, Yadav J, Yadav H, et al. Current advances and future prospects in production of recombinant insulin and other proteins to treat diabetes mellitus. Biotechnol Lett. 2022;44:643\u201369. https:\/\/doi.org\/10.1007\/s10529-022-03248-7.","journal-title":"Biotechnol Lett"},{"key":"4166_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S2213-8587(22)00134-0","volume":"10","author":"T Battelino","year":"2022","unstructured":"Battelino T, Bergenstal RM, Rodr\u00edguez A, et al. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10:407\u201317. https:\/\/doi.org\/10.1016\/S2213-8587(22)00134-0.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4166_CR18","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1111\/dom.14765","volume":"24","author":"M Kellerer","year":"2022","unstructured":"Kellerer M, Kaltoft MS, Lawson J, et al. Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial. Diabetes Obes Metab. 2022;24:1788\u201399. https:\/\/doi.org\/10.1111\/dom.14765.","journal-title":"Diabetes Obes Metab"},{"key":"4166_CR19","first-page":"64","volume":"76","author":"JC Philips","year":"2021","unstructured":"Philips JC, Paquot N. Ultra-rapid lispro (Lyumjev\u00ae). Rev Med Liege. 2021;76:64\u20138.","journal-title":"Rev Med Liege"},{"key":"4166_CR20","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/S0140-6736(23)02150-2","volume":"402","author":"D Russell-Jones","year":"2023","unstructured":"Russell-Jones D, Babazono T, Cailleteau R, et al. Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial. Lancet. 2023;402:1636\u201347. https:\/\/doi.org\/10.1016\/S0140-6736(23)02150-2.","journal-title":"Lancet"},{"key":"4166_CR21","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/dom.14921","volume":"25","author":"K Thammakosol","year":"2023","unstructured":"Thammakosol K, Sriphrapradang C. Effectiveness and safety of early insulin glargine administration in combination with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: a randomized controlled trial. Diabetes Obes Metab. 2023;25:815\u201322. https:\/\/doi.org\/10.1111\/dom.14921.","journal-title":"Diabetes Obes Metab"},{"key":"4166_CR22","doi-asserted-by":"publisher","first-page":"8942","DOI":"10.1021\/acs.jmedchem.1c00618","volume":"64","author":"TB Kjeldsen","year":"2021","unstructured":"Kjeldsen TB, Hub\u00e1lek F, Hj\u00f8rringgaard CU, et al. Molecular engineering of insulin icodec, the first acylated insulin analog for once-weekly administration in humans. J Med Chem. 2021;64:8942\u201350. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00618.","journal-title":"J Med Chem"},{"key":"4166_CR23","doi-asserted-by":"publisher","first-page":"22804","DOI":"10.1074\/jbc.M100575200","volume":"276","author":"I Petitpas","year":"2001","unstructured":"Petitpas I, Bhattacharya AA, Otagiri M, Curry S. Molecular basis of fatty acid specificity and long-chain fatty acid transport in human serum albumin. J Biol Chem. 2001;276:22804\u20139. https:\/\/doi.org\/10.1074\/jbc.M100575200.","journal-title":"J Biol Chem"},{"key":"4166_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1529\/biophysj.103.038018","volume":"87","author":"CF Wright","year":"2004","unstructured":"Wright CF, Thompson KC. Avidity effects in bivalent ligand\u2013receptor interactions. Biophys J. 2004;87:865\u201375. https:\/\/doi.org\/10.1529\/biophysj.103.038018.","journal-title":"Biophys J"},{"key":"4166_CR25","doi-asserted-by":"publisher","first-page":"920","DOI":"10.2337\/diabetes.49.6.999","volume":"49","author":"P Kurtzhals","year":"2000","unstructured":"Kurtzhals P, Havelund S, Jonassen I, et al. Insulin analogues with enhanced affinity for the insulin-like growth factor 1 receptor: relationship to mitogenicity. Diabetes. 2000;49:920\u20134. https:\/\/doi.org\/10.2337\/diabetes.49.6.999.","journal-title":"Diabetes"},{"key":"4166_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002301","volume":"9","author":"E Nishimura","year":"2021","unstructured":"Nishimura E, Pridal L, Glendorf T, et al. Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing. BMJ Open Diabetes Res Care. 2021;9: e002301. https:\/\/doi.org\/10.1136\/bmjdrc-2021-002301.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"4166_CR27","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1007\/s00125-013-2937-7","volume":"56","author":"N Tennagels","year":"2013","unstructured":"Tennagels N, Welte S, Hofmann M, et al. Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats. Diabetologia. 2013;56:1826\u201334. https:\/\/doi.org\/10.1007\/s00125-013-2937-7.","journal-title":"Diabetologia"},{"key":"4166_CR28","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1007\/s00125-024-06137-2","volume":"67","author":"R Trevisan","year":"2024","unstructured":"Trevisan R, Conti M, Ciardullo S. Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes. Diabetologia. 2024;67:1480\u201392. https:\/\/doi.org\/10.1007\/s00125-024-06137-2.","journal-title":"Diabetologia"},{"key":"4166_CR29","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.2337\/dc22-2235","volume":"46","author":"JM Bue-Valleskey","year":"2023","unstructured":"Bue-Valleskey JM, Kazda CM, Ma C, et al. Once-weekly basal insulin Fc demonstrated similar glycemic control to once-daily insulin degludec in insulin-naive patients with type 2 diabetes: a phase 2 randomized control trial. Diabetes Care. 2023;46:1060\u20137. https:\/\/doi.org\/10.2337\/dc22-2235.","journal-title":"Diabetes Care"},{"key":"4166_CR30","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1056\/NEJMoa2204601","volume":"387","author":"SA Arslanian","year":"2022","unstructured":"Arslanian SA, Hannon T, Zeitler P, et al. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. N Engl J Med. 2022;387:433\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2204601.","journal-title":"N Engl J Med"},{"key":"4166_CR31","first-page":"28","volume":"504","author":"M Pasarica","year":"2021","unstructured":"Pasarica M. Diabetes: device therapy. FP Essent. 2021;504:28\u201333.","journal-title":"FP Essent"},{"key":"4166_CR32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S2213-8587(22)00344-2","volume":"11","author":"ER Mathiesen","year":"2023","unstructured":"Mathiesen ER, Alibegovic AC, Corcoy R, et al. Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open-label, multinational, randomised, controlled, non-inferiority trial. Lancet Diabetes Endocrinol. 2023;11:86\u201395. https:\/\/doi.org\/10.1016\/S2213-8587(22)00344-2.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04166-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04166-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04166-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:54:14Z","timestamp":1791302054000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04166-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4166"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04166-5","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}